These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

837 related articles for article (PubMed ID: 23891555)

  • 1. Elucidating heterogeneity of IgA1 hinge-region O-glycosylation by use of MALDI-TOF/TOF mass spectrometry: role of cysteine alkylation during sample processing.
    Franc V; Řehulka P; Raus M; Stulík J; Novak J; Renfrow MB; Šebela M
    J Proteomics; 2013 Oct; 92():299-312. PubMed ID: 23891555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clustered O-glycans of IgA1: defining macro- and microheterogeneity by use of electron capture/transfer dissociation.
    Takahashi K; Wall SB; Suzuki H; Smith AD; Hall S; Poulsen K; Kilian M; Mobley JA; Julian BA; Mestecky J; Novak J; Renfrow MB
    Mol Cell Proteomics; 2010 Nov; 9(11):2545-57. PubMed ID: 20823119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation fourier transform-ion cyclotron resonance mass spectrometry.
    Renfrow MB; Cooper HJ; Tomana M; Kulhavy R; Hiki Y; Toma K; Emmett MR; Mestecky J; Marshall AG; Novak J
    J Biol Chem; 2005 May; 280(19):19136-45. PubMed ID: 15728186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Difference in IgA1 O-glycosylation between IgA deposition donors and IgA nephropathy recipients.
    Nakazawa S; Imamura R; Kawamura M; Kato T; Abe T; Namba T; Iwatani H; Yamanaka K; Uemura M; Kishikawa H; Nishimura K; Oka K; Tajiri M; Wada Y; Nonomura N
    Biochem Biophys Res Commun; 2019 Jan; 508(4):1106-1112. PubMed ID: 30553446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O-glycoforms of polymeric immunoglobulin A1 in the plasma of patients with IgA nephropathy are associated with pathological phenotypes.
    Yu G; Zhang Y; Meng B; Xie X; Wang Z; Ying W; Lv J; Zhang H
    Nephrol Dial Transplant; 2021 Dec; 37(1):33-41. PubMed ID: 34152412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of O-glycoforms of the IgA1 hinge region by sequential deglycosylation.
    Ohyama Y; Yamaguchi H; Nakajima K; Mizuno T; Fukamachi Y; Yokoi Y; Tsuboi N; Inaguma D; Hasegawa M; Renfrow MB; Novak J; Yuzawa Y; Takahashi K
    Sci Rep; 2020 Jan; 10(1):671. PubMed ID: 31959827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Hiki Y; Tanaka A; Kokubo T; Iwase H; Nishikido J; Hotta K; Kobayashi Y
    J Am Soc Nephrol; 1998 Apr; 9(4):577-82. PubMed ID: 9555659
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Dotz V; Visconti A; Lomax-Browne HJ; Clerc F; Hipgrave Ederveen AL; Medjeral-Thomas NR; Cook HT; Pickering MC; Wuhrer M; Falchi M
    J Am Soc Nephrol; 2021 Oct; 32(10):2455-2465. PubMed ID: 34127537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of O-glycosylation in the hinge region of human IgA1.
    Novak J; Tomana M; Kilian M; Coward L; Kulhavy R; Barnes S; Mestecky J
    Mol Immunol; 2000 Dec; 37(17):1047-56. PubMed ID: 11399322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: implications for IgA nephropathy.
    Renfrow MB; Mackay CL; Chalmers MJ; Julian BA; Mestecky J; Kilian M; Poulsen K; Emmett MR; Marshall AG; Novak J
    Anal Bioanal Chem; 2007 Nov; 389(5):1397-407. PubMed ID: 17712550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Potential of Plasma IgA1 O-Glycans in Discriminating IgA Nephropathy From Other Glomerular Diseases and Healthy Participants.
    Zhang S; Sun H; Zhang Z; Li M; Guo Z; Ye W; Cai G; Sun W; Li M
    Front Mol Biosci; 2022; 9():871615. PubMed ID: 35445079
    [No Abstract]   [Full Text] [Related]  

  • 12. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy.
    Hiki Y; Odani H; Takahashi M; Yasuda Y; Nishimoto A; Iwase H; Shinzato T; Kobayashi Y; Maeda K
    Kidney Int; 2001 Mar; 59(3):1077-85. PubMed ID: 11231363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy.
    Stuchlova Horynova M; Vrablikova A; Stewart TJ; Takahashi K; Czernekova L; Yamada K; Suzuki H; Julian BA; Renfrow MB; Novak J; Raska M
    Nephrol Dial Transplant; 2015 Feb; 30(2):234-8. PubMed ID: 25281698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathy.
    Takahashi K; Raska M; Stuchlova Horynova M; Hall SD; Poulsen K; Kilian M; Hiki Y; Yuzawa Y; Moldoveanu Z; Julian BA; Renfrow MB; Novak J
    PLoS One; 2014; 9(2):e99026. PubMed ID: 24918438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of the number of O-linked oligosaccharides per heavy chain of human serum IgA1 by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) analysis of the hinge glycopeptide.
    Iwase H; Tanaka A; Hiki Y; Kokubo T; Ishii-Karakasa I; Kobayashi Y; Hotta K
    J Biochem; 1996 Aug; 120(2):393-7. PubMed ID: 8889826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mass spectrometry analysis of IgA1 hinge region in patients with IgA nephropathy.
    Gastaldi D; Paradisi L; Baiocchi C; Medana C; Lo Duca G; Sena LM; Roccatello D
    J Nephrol; 2007; 20(6):689-95. PubMed ID: 18046671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: a comparative binding study.
    Gomes MM; Suzuki H; Brooks MT; Tomana M; Moldoveanu Z; Mestecky J; Julian BA; Novak J; Herr AB
    Biochemistry; 2010 Jul; 49(27):5671-82. PubMed ID: 20507092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturally occurring structural isomers in serum IgA1 o-glycosylation.
    Takahashi K; Smith AD; Poulsen K; Kilian M; Julian BA; Mestecky J; Novak J; Renfrow MB
    J Proteome Res; 2012 Feb; 11(2):692-702. PubMed ID: 22067045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human serum IgA1 is substituted with up to six O-glycans as shown by matrix assisted laser desorption ionisation time-of-flight mass spectrometry.
    Tarelli E; Smith AC; Hendry BM; Challacombe SJ; Pouria S
    Carbohydr Res; 2004 Sep; 339(13):2329-35. PubMed ID: 15337464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an enrichment-free one-pot sample preparation and ultra-high performance liquid chromatography-tandem mass spectrometry method to identify Immunoglobulin A1 hinge region O-glycoforms for Immunoglobulin A nephropathy.
    Chen HF; Kao CC; Ka SM; Wang SY; Chen MX; Chen GY; Weng TI; Lai RY; Yeh SC; Lin YC; Chen HH; Chang WC; Wu MS; Tsai IL
    J Chromatogr A; 2022 Dec; 1685():463589. PubMed ID: 36351322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.